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Epsilon  toxin  (Etx)  is  a -pore-forming  toxin  produced  by Clostridium  perfringens  toxinotypes  B and  D
and  plays  a  key  role  in the  pathogenesis  of enterotoxemia,  a  severe,  often  fatal  disease  of ruminants  that
causes  signiﬁcant  economic  losses  to  the  farming  industry  worldwide.  This  study  aimed to determine
the  potential  of a site-directed  mutant  of Etx  (Y30A-Y196A)  to be  exploited  as  a recombinant  vaccine
against  enterotoxemia.  Replacement  of  Y30  and  Y196  with  alanine  generated  a stable  variant  of  Etx  with
signiﬁcantly  reduced  cell  binding  and  cytotoxic  activities  in  MDCK.2  cells  relative  to wild  type toxinlostridium perfringens
psilon  toxin pore-forming toxin
nterotoxemia
ecombinant vaccine
(>430-fold  increase  in  CT50)  and  Y30A-Y196A  was  inactive  in  mice after  intraperitoneal  administration
of  trypsin  activated  toxin  at 1000×  the  expected  LD50 dose  of  trypsin  activated  wild  type  toxin.  Moreover,
polyclonal  antibody  raised  in rabbits  against  Y30A-Y196A  provided  protection  against  wild  type  toxin  in
an  in  vitro  neutralisation  assay.  These  data  suggest  that  Y30A-Y196A  mutant  could  form  the  basis  of an
improved  recombinant  vaccine  against  enterotoxemia.
©  2014  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
Clostridium perfringens is a Gram positive, anaerobe, spore form-
ng bacterium that is classiﬁed into ﬁve toxinotypes based on
roduction of the four typing toxins (-, -, -, and -toxins) [1].
psilon toxin (Etx), a -pore-forming toxin, is produced by C. per-
ringens strains that belong to toxinotypes B and D and plays a
ey role in the pathogenesis of enterotoxemia, a severe gastro-
ntestinal disease of ruminants that causes severe economic losses
o farmers worldwide.
C.  perfringens toxinotype B is the etiologic agent of dysentery in
ewborn lambs and haemorrhagic enteritis and enterotoxemia in
oats, calves and foals [2,3]. More recently, toxinotype B has been
etected in a human with a clinical presentation of multiple scle-
osis, providing clues for environment triggers of the disease [4]. C.
erfringens toxinotype D affects mainly sheep and lambs but also
auses infections in goats and calves [2,3].
The most important factor in initiating disease is the dis-
uption of the microbial balance in the gut due to overeating
∗ Corresponding author. Tel.: +44 0 1392 725177.
E-mail  address: m.bokori-brown@exeter.ac.uk (M.  Bokori-Brown).
ttp://dx.doi.org/10.1016/j.vaccine.2014.03.079
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/3.0/).
carbohydrate rich food, which causes proliferation of C. perfringens
and consequent overproduction of the toxin [2,5]. Overproduc-
tion of Etx causes increased intestinal permeability, facilitating
entry of the toxin into the bloodstream and its spread into vari-
ous organs, including the brain, lungs and kidneys. While infection
of the central nervous system results in neurological disorders, the
fatal effects on the organs often lead to sudden death [6,7].
For  full activity of the toxin, proteolytic processing is required,
with carboxy-terminal and amino-terminal peptides removed.
Toxin activation typically occurs in the gut either by digestive pro-
teases of the host, such as trypsin and chymotrypsin [8], or by
-protease produced by C. perfringens itself [9,10].
To prevent Etx-induced enterotoxemia in domesticated live-
stock, a number of commercial vaccines are available that have
been used extensively over the past decades. These vaccines are
based on either formaldehyde treated C. perfringens type D cul-
ture ﬁltrate or formaldehyde-inactivated recombinant wild type
toxin [11,12]. These vaccine preparations have several disadvan-
tages: (1) complete removal of free formaldehyde is required to
avoid possible toxic side effects, (2) toxoiding using formaldehyde
can show considerable batch to batch variation in immunogenicity
of these vaccines [12], (3) inﬂammatory responses following vacci-
nation can lead to reduced feed consumption [13] and (4) reversion
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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o toxicity may  occur in incompletely inactivated bacterial toxins.
herefore, there is a need to identify Etx variants with reduced
oxicity relative to wild type toxin. One approach to solving this
roblem is to develop recombinant vaccines based on site-directed
utants with markedly reduced toxicity.
Amino acid residues Y30 and Y196 have previously been iden-
iﬁed to play key roles in cell binding and thus, cytotoxicity of
tx [14,15]. Therefore, this study aimed to determine the potential
f a site-directed mutant of Etx with mutations Y30A and Y196A
ombined, termed Y30A-Y196A, to be exploited as a recombinant
accine against enterotoxemia.
.  Materials and methods
.1.  Expression and puriﬁcation of recombinant Etx mutant
30A-Y196A
The  gene encoding epsilon prototoxin, etxD, from C. perfringens
ype D strain NCTC 8346 was cloned into the expression vector pET-
6b(+) (Merck, Darmstadt, Germany) with a N-terminal PelB leader
eptide in place of the 13 amino acids N-terminal peptide sequence
residues KEISNTVSNEMSK) and with a C-terminal polyhistidine
6× His) tag as described previously [14].
Mutations Y30A and Y196A (amino acid numbering corresponds
o prototoxin without the 13 amino acids N-terminal peptide
equence) were introduced into the gene encoding epsilon pro-
otoxin (P-Etx) using the QuickChange Lightning Site-Directed
utagenesis Kit (Agilent Technologies, Inc. Santa Clara, US) accord-
ng to the manufacturer’s instructions. Recombinant P-Etx with
30A and Y196A mutations is termed Y30A-Y196A.
Recombinant Y30A-Y196A was expressed, puriﬁed and its ther-
ostability assessed as described previously [14].
.2.  Trypsin activation
Puriﬁed  recombinant Etx prototoxin was activated with trypsin,
PCK treated from bovine pancreas (Sigma-Aldrich Company Ltd.,
illingham, UK) for 1 h at room temperature and removal of the C-
erminal peptide sequence was assessed by SDS-PAGE as described
reviously [14].
.3.  Cell culture
MDCK.2 cells (ATCC-LGC Standards, Teddington, UK) and ACHN
ells (ECACC, Salisbury, UK) were routinely cultured in Eagle’s
inimum Essential Medium (EMEM; ATCC-LGC Standards, Ted-
ington, UK) supplemented with 10% Foetal Bovine Serum Gold
PAA, Pasching, Austria) at 37 ◦C in a humidiﬁed atmosphere of 95%
ir/5% CO2. The culture medium was replaced every 2–3 days. Cells
ere routinely detached by incubation in trypsin/EDTA and split as
ppropriate (typically 1:6 dilutions).
.4. Cytotoxicity assay
The  cytotoxic activity of trypsin-activated toxin toward MDCK.2
nd ACHN cells was determined by measuring the amount of lac-
ate dehydrogenase (LDH) released from the cytosol of lysed cells
nto the cell culture medium using the CytoTox 96 nonradioactive
ytotoxicity assay kit (Promega UK, Southampton, UK) as described
reviously [14]. The toxin dose required to kill 50% of the cell mono-
ayer (CT50) was determined by nonlinear regression analysis using
raphPad Prism 6 software (GraphPad Software, La Jolla, USA).
ll experiments were performed in triplicate with three technical
eplicates each.e 32 (2014) 2682–2687 2683
2.5. On-Cell Western assay
To  measure binding of prototoxin to MDCK.2 and ACHN cells
the On-Cell Western assay was  used as described previously [14].
Bound prototoxin was  detected with mouse anti-Etx monoclonal
Bio355 antibody (Bio-X Diagnostics S.P.R.L, Belgium) and IRDye
800CW goat anti-mouse IgG (H + L) antibody (LI-COR Biosciences,
Lincoln, USA) at 1:500 dilution each. To quantify the amount of ﬂu-
orescent signal, plates were imaged at 800 nm using the Odyssey
CLx infrared imaging system (LI-COR Biosciences, Lincoln, USA). The
binding activity of the mutant prototoxin was  expressed as the per-
centage of ﬂuorescence intensity relative to wild type prototoxin.
To compare the means of the On-Cell Western assay data, Two-Way
ANOVA analysis followed by Dunnett’s multiple comparisons test
was carried out using the GraphPad Prism 6 software (GraphPad
Software, La Jolla).
2.6.  Immunisation of rabbits with recombinant Y30A-Y196A
prototoxin
A  group of three New Zealand White rabbits were immu-
nised subcutaneously eight times on days 0, 14, 28, 42, 56, 70, 84
and 98 with a dose of 200 g puriﬁed recombinant Y30A-Y196A
prototoxin in phosphate buffered saline, pH 7.2 (PBS) (Immune
Systems Ltd., UK). For the initial immunisation Freund’s complete
adjuvant was used. The remainder immunisations used Freund’s
incomplete adjuvant. Pre-immune sera were collected on day 0
and harvest bleed was  collected on day 107. Post-inject antibod-
ies were detected by indirect ELISA (Immune Systems Ltd., UK).
In brief, a two-fold dilution series of each serum (ranging from
1:100 to 1:204,800) was prepared and added to a 96-well plate
coated with recombinant Y30A-Y196A prototoxin. A horseradish-
peroxidase-conjugated immunoglobulin antibody (IgG-HRP) was
used to detect bound antibody and plates were developed by the
addition of ABTS substrate. Titres were calculated by measuring the
dilution point where the absorbance at OD405nm dropped below 0.2
(4 times background).
2.7.  In vitro neutralisation assay
Trypsin-activated wild type Etx at a dose of 1× CT50 was incu-
bated for 1 h at room temperature with serial dilutions of either
Y30A-Y196A rabbit polyclonal antiserum or with a negative con-
trol antibody. The toxin-antibody mixtures were added to MDCK.2
cells plated in a 96-well plate and incubated at 37 ◦C for 3 h before
cytotoxicity was  measured by the LDH assay as described above.
Data were expressed relative to the LDH released from cells treated
with toxin only.
2.8.  Toxicity of trypsin activated Y30A-Y196A in mice
Groups of six female BALB/c mice were challenged by the
intraperitoneal route with a dose of trypsin-activated wild type
toxin corresponding to 1×, 10×, 100× or 1000× the expected LD50
dose of wild type toxin in phosphate buffered saline, pH 7.2 (PBS)
(2 ng, 20 ng, 200 ng or 2 g/mouse, respectively, in 100 l volume)
or with a dose of trypsin-activated Y30A-Y196A corresponding to
10× or 1000× the expected LD50 dose of wild type toxin in PBS
(20 ng or 2 g/mouse, respectively, in 100 l volume). The amounts
of trypsin-activated toxins used in this study are listed in Supple-
mentary Table 1. Control animals received 100 l PBS each. The
challenged animals were monitored continuously for the ﬁrst hour
post challenge, at hourly intervals until 6 h post challenge and then
at further 6 h intervals. The experiment was  terminated at 24 h post
challenge.
2684 M.  Bokori-Brown et al. / Vaccine 32 (2014) 2682–2687
Fig. 1. Recombinant Etx mutant Y30A-Y196A.
(A) Ribbon representation of recombinant epsilon prototoxin with side chains of amino acids Y30 and Y196 in Domain I shown in stick representation. Amino acid numbering
corresponds to prototoxin without the 13 amino acids N-terminal peptide sequence (PDB ID: 1UYJ). (B) SDS-PAGE analysis of puriﬁed Y30A-Y196A. Lane 1: Perfect Protein
marker, molecular mass is indicated in kDa to the left; lane 2: puriﬁed Y30A-Y196A prototoxin; Lane 3: trypsin activated Y30A-Y196A. Proteins were visualized by Coomassie
s oxin, 
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oltzmann  method using the Protein Thermal Shift software (Applied Biosystems).
The challenged animals were monitored continuously and
cored according to severity of clinical signs and neurological
ffects on a scale of 0–3, with 0 indicating no change and values
etween 1 and 3 indicating increasing severity. Details of the sco-
ing system are described in Supplementary Table 2. The onset of
eurological symptoms marked a humane endpoint and animals
howing neurological symptoms were euthanized. The use of ani-
als was conducted in accordance with the Animals (Scientiﬁc
rocedures) Act (1986) and was performed with the approval of
he on-site animal ethics committee.
. Results
.1. Identiﬁcation of recombinant Y30A-Y196A as a vaccine
andidate
In  an attempt to identify an Etx variant with markedly reduced
oxicity relative to wild type toxin that could be considered as
 recombinant vaccine candidate, we combined mutations Y30A
nd Y196A, generating the double tyrosine mutant, termed Y30A-
196A (Fig. 1A). Etx mutant Y30A-Y196A was  expressed and
uriﬁed as described in Materials and Methods. Puriﬁed recombi-
ant Y30A-Y196A prototoxin had an apparent molecular weight of
37 kDa as detected by SDS-PAGE (Fig. 1B, lane 2). Thermal stability
ssay [16] revealed that the melting temperature (Tm) of Y30A-
196A was similar to that of Etx with H149A mutation, providing
urther evidence that the double tyrosine mutant is folded correctly
Fig. 1C). The H149A mutation has previously been shown not to
ave an effect on the prototoxin tertiary structure [14].respectively. (C) Thermostability of Y30A-Y196A prototoxin was determined by the
ts represent the mean and standard deviation of triplicate samples.
3.2. Cytotoxic activity of trypsin activated Y30A-Y196A toward
MDCK.2  and ACHN cells
The  cytotoxic activity of trypsin activated Y30A-Y196A toward
MDCK.2 and ACHN cells were measured by the LDH assay. The
average dose of Y30A-Y196A required to kill 50% of MDCK.2 cells
was determined to be 1.49 M,  corresponding to an approximately
430-fold reduction in cytotoxic activity relative to wild type Etx
with a CT50 value of 3.47 nM (Fig. 2A). In contrast, the results of
our cytotoxicity assay in ACHN cells revealed that the cytotoxic
activity of trypsin activated Y30A-Y196A was equivalent to that
of wild type toxin (Fig. 2B). No LDH release could be measured
when MDCK.2 or ACHN cells were treated with trypsin activated Etx
mutant H106P [17], even at the maximum concentration of 10 M
tested.
3.3. Binding of Y30A-Y196A prototoxin to MDCK.2 and ACHN cells
We also evaluated the effect of Y30A-Y196A prototoxin on its
ability to bind to MDCK.2 and ACHN cells using the On-Cell West-
ern assay. As shown in Fig. 3, the ﬂuorescent signal of MDCK.2
cells treated with Y30A-Y196A prototoxin was similar to that
of cells treated with PBS only. In contrast, ACHN cells treated
with Y30A-Y196A prototoxin showed ﬂuorescence equivalent to
that of cells treated with wild type toxin (Fig. 3). Etx mutant
H106P showed similar binding to wild type toxin in both cell lines
(Fig. 3).
M. Bokori-Brown et al. / Vaccine 32 (2014) 2682–2687 2685
Fig. 2. Cytotoxicity of trypsin activated recombinant Y30A-Y196A toward MDCK.2
and ACHN cells. A two-fold dilution series (ranging from 10 M to 0.15 nM)  of each
activated toxin was  added to (A) MDCK.2 or (B) ACHN cells seeded into a 96-well
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Fig. 4. In vitro neutralisation assay. The polyclonal rabbit antiserum raised against
Y30A-Y196A  prototoxin is able to protect MDCK.2 cells against wild type Etx-late.  After 3 h incubation at 37 ◦C, the cell culture medium was  harvested and cyto-
oxicity was  measured using the CytoTox 96 nonradioactive cytotoxicity assay kit
Promega).
.4. Y30A-Y196A polyclonal antiserum raised in rabbits is able to
nduce  protective immunity in vitro
The mean IgG titre against puriﬁed Y30A-Y196A prototoxin was
easured by indirect ELISA on day 107 of the immunisation sched-
le and determined to be 1:16,000 (Immune Systems Ltd., UK),
ndicating that immunisation of rabbits with Y30A-Y196A proto-
oxin induced a speciﬁc antibody response.
To test the ability of the polyclonal antiserum raised in rabbits
gainst Y30A-Y196A prototoxin to neutralise the cytotoxic activity
f wild type Etx in MDCK.2 cells, we used the in vitro neutralisation
ssay as described in Materials and Methods. As shown in Fig. 4,
he polyclonal antiserum raised against Y30A-Y196A prototoxin
as able to protect MDCK.2 cells against wild type Etx-induced
ig. 3. Binding of Y30A-Y196A prototoxin to MDCK.2 and ACHN cells.
uriﬁed  recombinant prototoxins (5 M)  were added to wells containing MDCK.2
r  ACHN cells. After 20 min  incubation at 37 ◦C, cells were ﬁxed and bound protein
as  detected with mouse anti-Etx and IRDye 800CW goat anti-mouse antibod-
es.  Asterisks denote a statistically signiﬁcant difference (**** p < 0.0001; two-way
NOVA  analysis) relative to wild type control. Each bar represents the means ± SEM
f three independent experiments performed in triplicate.induced cytotoxicity in a dose-dependent manner (up to dilution 26, which
corresponds  to 0.195 g/ml antibody concentration).
cytotoxicity in a dose-dependent manner (up to dilution 26, which
corresponds to 0.2 g/ml antibody concentration). In contrast, the
negative control antibody did not inhibit Etx-induced cytotoxicity
at any of the doses tested.
3.5.  Toxicity of Y30A-Y196A in mice
Our in vitro toxicity data revealed that trypsin activated Y30A-
Y196A has differential cytototoxic activity toward MDCK.2 and
ACHN cells, showing markedly reduced cytotoxicity in MDCK.2
cells but equivalent cytotoxic activity to wild type toxin in ACHN
cells. Therefore, we  next tested the toxicity of trypsin activated
Y30A-Y196A after intraperitoneal administration in groups of six
mice.
First, we determined the toxicity of trypsin activated wild type
Etx after intraperitoneal administration in groups of six mice. Mice
injected with 1× and 10× LD50 of wild type toxin survived for 24 h
without showing any signs of intoxication, whereas a dose of 100×
LD50 resulted in death within 180 min  post-injection and a dose of
1000× LD50 resulted in death by 45.5 min  post-injection.
To  test the toxicity of Y30A-Y196A in vivo, mice were injected
with trypsin activated Y30A-Y196A at a dose of 1000× LD50 of
trypsin-activated wild type toxin. Control animals received PBS
only. As shown in Fig. 5A, mice injected with either PBS or Y30A-
Y196A survived for 24 h without showing any signs of intoxication,
while mice injected with wild type toxin died within 50 min.
Fig. 5. Toxicity of trypsin activated Y30A-Y196A after intraperitoneal injection of
mice. (A) Kaplan-Meier survival curves of female BALB/c mice over a 24 h period
following  intraperitoneal injection of 1000× LD50 dose of trypsin-activated wild
type  or Y30A-Y196A toxins. Control animals received PBS only. Animals showing
neurological signs were euthanized at a humane endpoint.
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. Discussion
Recently, we have determined the roles of surface exposed tyro-
ine residues in domain I of Etx mediating binding and toxicity of
tx to target cells [14]. This study was conducted to determine
he potential of the site-directed Etx mutant Y30A-Y196A to be
xploited as a recombinant vaccine against enterotoxemia.
Site-directed mutants of Etx with markedly reduced toxicity
ave previously been produced [17,18]. The site-directed mutant
106P with no activity has been shown to be non-toxic to mice
fter intravenous administration of periplasmic extracts from
scherichia coli [17]. Moreover, immunisation of mice with H106P
utant resulted in the induction of a speciﬁc antibody response and
mmunised mice were protected against a subsequent challenge
f 1000× LD50 dose of wild type Etx administered by the intra-
enous route [17]. The low toxicity site-directed Etx mutant F199E
as recently been shown to protect immunised mice against a 100×
D50 dose of recombinant wild type Etx toxin [18]. While these Etx
utants are promising vaccine candidates against enterotoxemia,
ecombinant Etx vaccines derived from site-directed mutants with
 single mutation risk reversion to full activity in a DNA based vac-
ine or in a live vaccine vector such as Salmonella. Therefore, the
se of recombinant Etx vaccines derived from low toxicity site-
irected mutants with two mutations, such as the Y30A-Y196A
utant developed in this study, would greatly reduce the risk of
eversion to full activity, making Y30A-Y196A an ideal recombinant
accine candidate.
Simultaneous replacement of Y30 and Y196 with alanine gen-
rated a stable variant of Etx that showed signiﬁcantly reduced
ell binding and cytotoxic activities in MDCK.2 cells but not in
CHN cells. Single mutants Y30A and Y196A have previously been
hown to have 27-fold and 10-fold reduction in cytotoxicity toward
DCK.2 cells relative to Etx-H149A (with an average CT50 of 12 nM),
espectively [14], which corresponds to 93-fold and 34-fold reduc-
ion in cytotoxic activity relative to wild type Etx (with an average
T50 value of 3.47 nM), respectively. Mutant Y30A-Y196A in this
tudy showed 430-fold reduction in cytotoxic activity relative to
ild type Etx in MDCK.2 cells, suggesting that mutations Y30A and
196A have a cumulative effect on reducing the ability of Etx to lyse
DCK.2 cells. In contrast, the double mutant Y30A-Y196A showed
o reduction in cytotoxic activity in ACHN cells relative to wild
ype toxin, further supporting the ﬁndings of our previous study
hat surface exposed tyrosine residues in domain I do not mediate
ytotoxicity of Etx in ACHN cells [14]. These data suggest that Etx
ay have a dual mechanism of binding to target cells, similar to
taphylococcus aureus alpha hemolysin (-HL) [19].
Due to the differential activity of mutant Y30A-Y196A in
DCK.2 and ACHN cells, we assessed the safety of this variant
or immunisation by intraperitoneal administration of trypsin acti-
ated Y30A-Y196A to mice. There is a scarcity of data on the LD50
ose of Etx in the literature when given by the intraperitoneal route
o mice. Thus, this study also determined the toxicity of trypsin acti-
ated wild type Etx after intraperitoneal administration in groups
f six mice. In previous studies trypsin activated Etx has been shown
o have a LD50 dose ranging from 70 ng/kg [20] to 320 ng/kg [10]
hen administered by the intravenous route to mice. There is less
ata on the LD50 dose of wild type Etx when given by the intraperi-
oneal route to mice. Intraperitoneal injection of Etx prototoxin
nto Fisher rats with an average weight of 350 g produced a LD50 of
4 g/animal or 40 g/kg of body weight [21]. Taking into account
hat Etx prototoxin is >1000-fold less active compared to acti-
ated toxin [22], intraperitoneal injection of activated Etx would
ield a LD50 of approximately 40 ng/kg of body weight. This ﬁgure
orrelates well with the consensus LD50 value of 100 ng/kg after
ntravenous administration of activated Etx to mice [23]. There-
ore, our working assumption was that the LD50 value of trypsine 32 (2014) 2682–2687
activated  wild type Etx after intraperitoneal administration to mice
is 100 ng/kg of body weight or approximately 2 ng/mouse with an
average weight of 20 g. Mice injected with 2 ng or 20 ng trypsin acti-
vated wild type Etx by the intraperitoneal route survived for 24 h
without showing any signs of intoxication, whereas a dose of 200 ng
trypsin activated wild type Etx resulted in death within 180 min
post-injection, suggesting that the LD50 value of trypsin activated
wild type Etx administered to mice by the intraperitoneal route is
between 20 ng and 200 ng/mouse, extrapolated to 1–10 g/kg of
body weight.
We  showed that Y30A-Y196A is inactive in mice after intraperi-
toneal administration of up to 1000× the expected LD50 dose of
wild type toxin, mirroring our in vitro cytotoxicity data in MDCK.2
cells. We  also showed that polyclonal antibody raised against Y30A-
Y196A provides protection against wild type toxin in an in vitro
neutralisation assay.
In  conclusion, this study showed that recombinant Etx mutant
Y30A-Y196A is non-toxic to mice, demonstrating the potential of
Y30A-Y196A mutant to form the basis of an improved recombi-
nant vaccine against enterotoxemia in ruminants. Further studies
are needed to determine whether Y30A-Y196A is able to induce
protection against experimental enterotoxemia in sheep.
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